Nasdaq1mon
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...
Mena FN18d
Biodexa Announces Allowance Of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“Erapa”) And Use
Stephen Stamp, CEO and CFO of Biodexa, commented“The FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity from ...
Nasdaq1mon
Biodexa Pharmaceuticals Receives FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...
Morningstar1mon
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Morningstar brands and products Company Portfolio ...